Mead P S, Griffin P M
Foodborne and Diarrheal Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Lancet. 1998 Oct 10;352(9135):1207-12. doi: 10.1016/S0140-6736(98)01267-7.
Escherichia coli O157 was first identified as a human pathogen in 1982. One of several Shiga toxin-producing serotypes known to cause human illness, the organism probably evolved through horizontal acquisition of genes for Shiga toxins and other virulence factors. E. coli O157 is found regularly in the faeces of healthy cattle, and is transmitted to humans through contaminated food, water, and direct contact with infected people or animals. Human infection is associated with a wide range of clinical illness, including asymptomatic shedding, non-bloody diarrhoea, haemorrhagic colitis, haemolytic uraemic syndrome, and death. Since laboratory practices vary, physicians need to know whether laboratories in their area routinely test for E. coli O157 in stool specimens. Treatment with antimicrobial agents remains controversial: some studies suggest that treatment may precipitate haemolytic uraemic syndrome, and other studies suggest no effect or even a protective effect. Physicians can help to prevent E. coli O157 infections by counselling patients about the hazards of consuming undercooked ground meat or unpasteurised milk products and juices, and about the importance of handwashing to prevent the spread of diarrhoeal illness, and by informing public-health authorities when they see unusual numbers of cases of bloody diarrhoea or haemolytic uraemic syndrome.
1982年,大肠杆菌O157首次被确认为人类病原体。它是已知的几种能产生志贺毒素并导致人类疾病的血清型之一,该生物体可能通过水平获取志贺毒素和其他毒力因子的基因而进化。大肠杆菌O157经常在健康牛的粪便中被发现,并通过受污染的食物、水以及与受感染的人或动物直接接触传播给人类。人类感染与多种临床疾病有关,包括无症状排毒、非血性腹泻、出血性结肠炎、溶血性尿毒综合征以及死亡。由于实验室操作各不相同,医生需要了解所在地区的实验室是否常规对粪便标本进行大肠杆菌O157检测。使用抗菌药物治疗仍存在争议:一些研究表明治疗可能会引发溶血性尿毒综合征,而其他研究则表明没有效果甚至有保护作用。医生可以通过向患者提供关于食用未煮熟的绞肉或未经巴氏消毒的奶制品及果汁的危害以及洗手对于预防腹泻疾病传播的重要性的咨询,并在发现异常数量的血性腹泻或溶血性尿毒综合征病例时通知公共卫生当局,来帮助预防大肠杆菌O157感染。